# Adjuvant Development  in the context of vaccines for Zika, Dengue  and West Nile virus

> **NIH NIH N01** · VIROVAX LLC · 2022 · $1,983,970

## Abstract

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.

## Key facts

- **NIH application ID:** 10643693
- **Project number:** 272201800049C-P00010-9999-1
- **Recipient organization:** VIROVAX LLC
- **Principal Investigator:** SUNIL DAVID
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,983,970
- **Award type:** —
- **Project period:** 2018-09-30 → 2023-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10643693

## Citation

> US National Institutes of Health, RePORTER application 10643693, Adjuvant Development  in the context of vaccines for Zika, Dengue  and West Nile virus (272201800049C-P00010-9999-1). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10643693. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*